Clinical trials transformation

AI has huge potential to transform the end-to-end trials process. Ethical concerns and regulatory uncertainty will play a significant role in influencing how quickly the industry is able to move, and there will be the potential for new organizations to break out in this space. These will be data-rich organizations that build their platforms with their partners to generate trust and that best solve the problem of validating continually evolving models.”

Although aligning on a vision, measuring progress, and creating a culture of accountability doesn’t happen overnight, it is imperative that we keep pushing forward to improve the representation of diverse populations in clinical trials.”

With the level of adoption of decentralised trial methodologies continuing to grow despite the predicted pullback following the lessening of pandemic restrictions, all organisations should be asking how they can do more, and move faster, toward more human-centric trial designs.”

The generation of multiple types of complex organoids along with the innovation in optical setups and omics techniques is providing researchers with new, more extensive raw data that requires novel analytics tools and platforms.”